

## Rigel to Present at Piper Jaffray Health Care Conference

SOUTH SAN FRANCISCO, Calif., Nov. 23, 2010 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the 22nd Annual Piper Jaffray Health Care Conference in New York on Wednesday, December 1st at 3:00 p.m. EST.

To access the live audio webcast or the subsequent archived recording, log on to <u>www.rigel.com</u>. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

## About Rigel (<u>www.rigel.com</u>)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune disorders, as well as muscle and metabolic diseases. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral syk inhibitor that has started its phase 3 clinical trial program for rheumatoid arthritis, and R343, an inhaled syk inhibitor that is in clinical trials for asthma.

Contact: Ryan Maynard Phone: 650.624.1284 Email: <u>invrel@rigel.com</u>

SOURCE Rigel Pharmaceuticals, Inc.